INTRODUCTION

Sarcopenia is an age-related muscle disorder characterized by the loss of skeletal muscle mass and function. Sarcopenia comprises myopenia (a decline in muscle mass) and dynapenia (a decline in muscle strength); thus, it leads to compromised physical function, high risk of disability, and low quality of life. According to the literature, the prevalence of sarcopenia in people aged 60–70 years old is 5–13%, while it ranges from 11 to 50% in people older than 80 years. Current estimates suggest that approximately 200 million people worldwide suffer from sarcopenia to a degree that affects their life’s quality. Thus, the development of therapeutic strategies for the management of sarcopenia is highly required.

Jaeumganghwa-tang (JGT, Zi-ying-jiang-huo-tang in Chinese and Jin-koka-to in Japanese) is one of the most widely prescribed traditional herbs in East Asia. JGT is composed of 12 medicinal herbs: Paeoniae Radix, Angelicae Gigantis Radix, Rehmanniae Radix Preparata, Atractylodis Rhizoma Alba, Liriopis Tuber, Rehmanniae Radix Crudus, Citri Unshiu Pericarpium, Anemarrhenae Rhizoma, Phellodendri Cortex, Glycyrrhizae Radix et Rhizoma, Zingiberis Rhizoma Crudus, and Zizyphi Fructus.

Thus, in this study, we aimed to investigate the effects of JGT on muscle mass and function in aged mice. To elucidate the underlying molecular mechanisms, we assessed the protein expression of TGF-β in the muscle tissue.
METHODS

Animal treatment
Young and old male C57BL/6 mice (aged 5 and 19 months, respectively) were obtained from the Laboratory Animal Resource Center in Korea Basic Science Institute (KBASI, Gwangju, Korea) and housed in a specific pathogen-free facility under constant conditions (12 h light-dark cycle at 22 ± 1 °C and 55 ± 5% humidity). After an acclimation period of 1 week, the mice were randomly divided into four groups as follows: young mice administered vehicle (Y:Con, n = 4); young mice administered JGT (Y:JGT, n = 4); old mice administered vehicle (O:Con, n = 8); and old mice administered JGT (O:JGT, n = 8). JGT was purchased from Han Kook Shin Yak Pharmaceutical Co., Ltd. (Chungnam, Korea) in the form of powdered granules. The chemical composition of these granules was verified based on the company standards (Table 1). JGT was dissolved in saline and orally administered to the mice at a dose of 75 mg/d for 6 weeks. This dose was calculated from the adult human dose (15 g/d)\(^\text{13}\). At the end of the experimental period, muscle strength was examined; then, mice were anesthetized with diethyl ether and killed, and muscle tissues were collected. All animal experiments were performed in accordance with the guidelines of the Animal Care and Use Committee of the Korea Institute of Oriental Medicine (KIOM, Daejeon, Korea) with reference number #15-083.

Wire hang test
A wire mesh grid (15 × 25 cm) was used to measure the muscle strength as follows; the mouse was placed on the wire mesh grid 40 cm above a foam cushion, then the mesh was inverted so that the mouse is forced to hang to the wire using its four limbs. The timer was activated upon inversion and the hanging time was recorded as the duration for which the mouse keeps hanging before falling on the cushion\(^\text{12}\).

Tissue collection
The tibialis anterior (TA) and gastrocnemius (GC) muscles were immediately dissected and washed in phosphate-buffered saline (PBS) after anesthesia. Then, excess PBS was removed by blotting on a paper towel and the muscles were weighed using an analytical scale (Mettler-Toledo International Inc., model# ML204T). For protein extraction, tissues were snap-frozen in liquid nitrogen and stored at −80 °C; for histology (hematoxylin and eosin (H&E) staining) and immunohistochemistry, tissues were fixed via overnight immersion in 10% phosphate-buffered formalin.

Western blot analysis of muscle tissues
Western blot assays were carried out using total cellular protein. The frozen muscle was homogenized in RIPA buffer (20 mL/g of tissue) (Thermo Scientific, Rockford, IL) containing protease and phosphatase inhibitors according to the manufacturer’s instructions. The protein concentration was determined using a Bio-Rad Protein Assay reagent (Bio-Rad, Hercules, CA). Equal amounts of protein extracts (20 μg) were resolved via 4–20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane was incubated with a blocking solution (5% skimmed milk in Tris-buffered saline (PBS) after anesthesia. Then, excess PBS was removed by blotting on a paper towel and the muscles were weighed using an analytical scale (Mettler-Toledo International Inc., model# ML204T). For protein extraction, tissues were snap-frozen in liquid nitrogen and stored at −80 °C; for histology (hematoxylin and eosin (H&E) staining) and immunohistochemistry, tissues were fixed via overnight immersion in 10% phosphate-buffered formalin.

Histological analysis of muscle tissues
Mouse TA and GC muscle tissues were fixed in 10% phosphate-buffered formalin for 24 h and embedded in paraffin; then, 4-μm-thick sections were cut and stained with H&E. To analyze the muscle fiber phenotype, muscle tissues were imaged using a microscope (BX43, Olympus, Japan).

Table 1. The components of JGT and their compounded rates.

| Scientific name | Latin name | Compounded rates (%) |
|-----------------|------------|----------------------|
| Angelica gigas  | Angelicae Gigantis Radix | 10.2 |
| Paeonia lactiflora | Paeoniae Radix | 10.2 |
| Rehmannia glutinosa | Rehmanniae Radix Crudus | 10.2 |
| Asparagus cochinchinensis | Asparagi Tuber | 10.2 |
| Atractyloides japonica | Atractyloids Rhizoma Alba | 12.3 |
| Anemarrhena asphodeloides | Anemarrhenae Rhizoma | 6.1 |
| Phellodendron amurense | Phellodendri Cortex | 6.1 |
| Glycyrrhiza uralensis | Glycyrrhizeae Radix et Rhizoma | 6.1 |
| Zizyphus jujube | Zizyphi Fructus | 4.1 |
| Zingiber officinale | Zingiberis Rhizoma Crudus | 4.1 |
| Liriopis platyphylla | Liniopis Tuber | 10.2 |
| Citrus unshiu | Citri Unshius | 10.2 |
Immunohistochemical analysis of muscle tissues
Formalin-fixed paraffin-embedded muscle tissue sections were deparaffinized and rehydrated then boiled in 10 mM sodium citrate, pH 6.0, with 0.05% Tween-20 for 30 min for antigen retrieval. Sections were blocked in normal serum and incubated with TGF-β (1/500) antibodies overnight. Endogenous HRP activity was quenched by incubation with 3% hydrogen peroxide for 10 min. Secondary antibody staining was performed using the Polink-2 Plus HRP kit (GIBI Labs, Bothell, WA) and detected with 3,3’-diaminobenzidine (DAB). Negative controls for immunohistochemistry were run by incubating the sections with non-immune serum instead of the primary antibody.

Statistical analysis
Data are expressed as the mean ± standard error of the mean (SEM). Data were analyzed using one-way analysis of variance and Dunnett’s multiple comparisons tests using Prism software (GraphPad Software Inc., La Jolla, CA). *P values lower than 0.05 indicated statistical significance.

RESULTS

JGT improves muscle strength in aged mice
In order to examine the effects of JGT treatment on age-associated muscle weakness, both young (5-month-old) and old (19-month-old) mice treated with saline or JGT for 6 weeks were exposed to the wire hang test. During the treatment period, no significant differences in body weights were observed between the young and old control and JGT-treated mice (Fig. 1A). The wire hang test was performed during the last week of the treatment period. We measured the maximum duration for which the mice remained hanging to the inverted wire mesh grid before falling. This duration was significantly shorter in the old mice than in the young mice. However, JGT-treated old mice hung for a longer duration than the old control mice. JGT treatment had no effect on the hanging duration in the young mice groups (Fig. 1B). These results suggest that JGT has beneficial effects on muscle strength.

JGT increases muscle mass in aged mice
In order to examine the effect of JGT treatment on age-associated muscle loss, we weighed the TA and GC muscles of all the mice after biopsy. As expected, aging resulted in a significant decline in the weights of both muscles. The JGT-treated old mice demonstrated an increase in the weights of the TA muscles, but this increase was not significant (Fig. 2A). However, JGT treatment significantly increased the weights of the GC muscles in the JGT-treated old mice compared to the old control mice (Fig. 2B). JGT treatment had no effect on the weights of either muscle in the young mice groups.

JGT ameliorates muscle damage in aged mice
Histological analysis of TA and GC muscles via H&E staining revealed significant muscle damage in the old
mice groups. As shown in Fig. 3, the muscles of the old mice showed a reduction in the muscle fiber size and an increase in the amount of connective tissue. These age-related muscle changes were found to be significantly improved in the JGT-treated mice compared with the age-matched control mice (Fig. 3).

**JGT reduces expression of TGF-β in aged mice**

We investigated the effect of JGT on the expression of TGF-β, one of the most potent muscle atrophy-inducing cytokines. To assess whether JGT affects the local intramuscular levels of TGF-β in old mice, western blotting (Fig. 4) and immunohistochemistry were performed (Fig. 5) on the TA and GC muscles after biopsy. As expected, the intramuscular levels of TGF-β in the old mice were higher than those in the young mice. JGT treatment dramatically suppressed the expression of TGF-β in both the TA and GC muscles in the old mice. However, it had no effect on the intramuscular levels of TGF-β in the young mice groups.

**DISCUSSION**

Sarcopenia, the loss of muscle mass and function with aging, is one of the most sensitive indicators of decrepitude. It has been reported that the estimated direct healthcare expenses due to sarcopenia are 18.5 billion dollars...
per year in the United States\textsuperscript{14}. Because of the global increase in the elderly population, the economic cost for sarcopenia is expected to increase exponentially.

Various interventions have been investigated for the treatment of sarcopenia. To date, exercise is the most effective strategy. It has been reported that short-term resistance exercise training maintains a modest increment in the rate of muscle protein synthesis, contributes to muscle hypertrophy, and improves muscle strength in elderly people\textsuperscript{15}. However, when sarcopenia develops to physical impairment, it is impossible to improve the case through exercise only. Thus, in this case, alternative pharmaceutical interventions need to be considered.

Several pharmaceutical interventions have been investigated for their ability to treat sarcopenia. For example, \(\beta\)-hydroxy \(\beta\)-methylbutyrate (HMB), a metabolite of leucine that is sold as a dietary supplement, was found to be effective in preventing muscle loss in individuals with sarcopenia\textsuperscript{16}. Testosterone was also investigated for the treatment of sarcopenia, and seemed to have some beneficial effects on muscle strength and mass, but was not approved because of its several side effects related to sexual function\textsuperscript{17}. No medications have been approved for the treatment of sarcopenia until now.

Traditional herbal formulas have been used to treat various diseases for thousands of years in Korea, China, Japan, and other Asian countries\textsuperscript{18}. Since traditional herbal formulas are generally cheaper, less toxic, and have fewer side effects than chemical drugs, they are usually applied as alternative medicines in clinical practice to treat a wide range of human diseases\textsuperscript{19}. Recently, the potential pharmaceutical effect of traditional herbal formulas on sarcopenia has been investigated. In an experiment conducted on C2C12 muscle cell line, hachimijijogan was found to enhance skeletal muscle myoblast proliferation\textsuperscript{20}. In addition, goshajinkigan was found to suppress sarcopenia via the insulin/IGF-1 signaling pathway. It also maintained the expression of mitochondria-related transcription factors and suppressed the expression of TNF-\(\alpha\) in senescence-accelerated mice\textsuperscript{21}. In addition, it further augmented resistance to exercise-induced muscle protein synthesis via the mTORC1 signaling pathway\textsuperscript{22}.

JGT has been prescribed for the prevention and treatment of age-related diseases for a long time. The purpose of this study was to investigate the effect of JGT on sarcopenia. Our results showed that the treatment of old mice with JGT improved muscle strength, increased skeletal muscle mass, and ameliorated muscle damage. Several factors are known to contribute to the age-related loss of muscle mass and strength. From these factors, we focused on TGF-\(\beta\), which is a potent inducer of muscle atrophy\textsuperscript{23-26}. Levels of TGF-\(\beta\) are elevated in various muscle diseases including sarcopenia\textsuperscript{27}. In addition, the pathogenesis of sarcopenia involves alterations in the TGF-\(\beta\) signaling pathway\textsuperscript{13}. In this study, we demonstrated that JGT treatment suppressed the intramuscular expression of TGF-\(\beta\) in old mice. Although further studies are still required, the beneficial effects of JGT on muscle mass and strength shown in our study suggest that it might serve as an effective treatment for sarcopenia.

ACKNOWLEDGEMENTS

This work was supported by a grant from the Korea Institute of Oriental Medicine (No. K16052).

REFERENCES

1. Cesari M, Landi F, Veillas B, Bernabei R, Marzetti E. Sarcopenia and physical frailty: two sides of the same coin. Front Aging Neurosci. 2014;6:192.
2. Evans WJ. What is sarcopenia? J Gerontol A Biol Sci Med Sci. 1995;50:5-8.
3. Phillips SM. Nutritional supplements in support of resistance exercise to counter age-related sarcopenia. Adv Nutr. 2015;6:452-60.
4. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755-63.
5. Janssen I. The epidemiology of sarcopenia. Clin Geriatr Med. 2011;27:355-63.
6. Heo J. Dongui Bogam Korea. Bubin Publishers. 2011;223.
7. Pharmacopoeia of the People’s Republic of China 2010. Chinese Pharmacopoeia Commission. 2011.
8. Kim A, Im M, Hwang YH, Yang HJ, Ma JY. Jaeumganghwa-Tang Induces Apoptosis via the Mitochondrial Pathway and Lactobacillus Fermentation Enhances Its Anti-Cancer Activity in HT1080 Human Fibrosarcoma Cells. PLoS One. 2015;10:e0127898.
9. Kim YK, Kim HH, Kim WS, Park HJ, Moon G, Kim DW, Won JH. Inhibitory effect of jaeumganghwa-tang on allergic inflammatory reaction. Journal of Korean oriental internal medicine. 2004;25:174-82.
10. Shin IS, Lee MY, Lim HS, Seo CS, Ha HK, Shin HK. Jaeumganghwa-tang, a traditional herbal formula inhibits the development of benign prostatic hyperplasia in rats. J Appl Biol Chem. 2012;55:205-12.
11. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659-61.
12. Deacon RM. Measuring the strength of mice. J Vis Exp. 2013.
13. Chen JL, Colgan TD, Walton KL, Gregorevic P, Harrison CA. The TGF-beta Signalling Network in Muscle Development, Adaptation and Disease. Adv Exp Med Biol. 2016;900:97-131.
14. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004;52:860-5.
15. Yarasheski KE. Exercise, aging, and muscle protein metabolism. J Gerontol A Biol Sci Med Sci. 2003;58:M918-22.
16. Wu H, Xia Y, Jiang J, Du H, Guo X, Liu X, et al. Effect of beta-hydroxy-beta-methylbutyrate supplementation on muscle loss in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2015;61:168-75.
17. Wakabayashi H, Sakuma K. Comprehensive approach to sarcopenia treatment. *Curr Clin Pharmacol*. 2014;9:171-80.
18. Jiang W. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. *Trends Pharmacol Sci*. 2005;26:558-63.
19. Hsiao WL, Liu L. The role of traditional Chinese herbal medicines in cancer therapy---from TCM theory to mechanistic insights. *Planta Med*. 2010;76:1118-31.
20. Takeda T, Tsuji K, Li B, Tadakawa M, Yaegashi N. Proliferative effect of Hachimijiogan, a Japanese herbal medicine, in C2C12 skeletal muscle cells. *Clin Interv Aging*. 2015;10:445-51.
21. Kishida Y, Kagawa S, Arimitsu J, Nakanishi M, Sakashita N, Otsuka S, Yoshikawa H, Hagihara K. Go-sha-jinki-Gan (GJG), a traditional Japanese herbal medicine, protects against sarcopenia in senescence-accelerated mice. *Phytomedicine*. 2015;22:16-22.
22. Kido K, Sato K, Makanae Y, Ato S, Hayashi T, Fujita S. Herbal supplement Kamishimotsuto augments resistance exercise-induced mTORC1 signaling in rat skeletal muscle. *Nutrition*. 2016;32:108-13.
23. Hall DT, Ma JF, Marco SD, Gallouzi IE. Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia. *Aging (Albany NY)*. 2011;3:702-15.
24. Marzetti E, Privitera G, Simili V, Wohlgenuth SE, Aulisa L, Pahor M, Leeuwenburgh C. Multiple pathways to the same end: mechanisms of myonuclear apoptosis in sarcopenia of aging. *Scientific World Journal*. 2010;10:340-9.
25. Kob R, Bollheimer LC, Bertsch T, Fellner C, Djukic M, Sieber CC, Fischer BE. Sarcopenic obesity: molecular clues to a better understanding of its pathogenesis? *Biogerontology*. 2015;16:15-29.
26. Navarro A, Lopez-Cepero JM, Sanchez del Pino MJ. Skeletal muscle and aging. *Front Biosci*. 2001;6:26-44.
27. Burks TN, Cohn RD. Role of TGF-beta signaling in inherited and acquired myopathies. *Skeletal Muscle*. 2011;1:19.